vIndianz.com (Aug. 15, 2009) — Drugmaker GlaxoSmithKline says it has started testing its swine flu vaccine in humans. The company has already received orders for more than 96 million doses of vaccine for H1N1 swine flu in the past two weeks.
UK drug manufacturer GlaxoSmithKline plans to conduct 16 clinical trials of its swine flu vaccine in more than 9,000 people in Europe, Canada and the United States.
Glaxo said the first trial of its swine flu vaccine in Germany of adults ages 18 to 60. Those data will be shared with drug regulatory authorities so they can make an early decision whether to license the vaccine.
Both Europe and the U.S. have fast-track approval systems for the swine flu vaccine.
Two other major drugmakers, Novartis and Sanofi-Aventis, began testing their swine flu vaccines earlier this month.
The United States has also ordered $250 million worth of vaccine ingredients. The company says it will donate 50 million doses of swine flu vaccine to the World Health Organization for use in poorer countries.
The World Health Organization (WHO) declared H1N1 flu a pandemic earlier this year. Since swine flu emerged in April, it has killed at least 1,462 people worldwide.
Further Reading- India Faces Drought and Swine Flu
- One Flu Over the Health Care Nest
- Drug companies cut vaccine prices – BBC News
- a Vaccine Against the ‘Silent Killer’ – ABC News
- Pfizer Pneumonia Shot Shown Effective in Ages 50 and Older – Bloomberg
- Vaccine call after swine flu deaths – The Press Association
- No proof of drug industry sway on WHO in pandemic: report – Reuters
- Swine flu jab: narcolepsy link investigated – Telegraph.co.uk
- Drug Companies Slash Vaccine Prices For Poorest Countries – Wall Street Journal
- GSK, Merck lead vaccine price cuts for GAVI – FiercePharma
Stay updated! Follow us on twitter and subscribe to our feed via Feedburner.
No Comments